Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, when the drug Daraxonrasib will be available to pancreatic cancer patients on the NHS.

Daraxonrasib is not currently licensed in the United Kingdom. Should the manufacturer submit an application to the Medicines and Healthcare products Regulatory Agency (MHRA) for a product licence, the MHRA has processes in place to review and assess its benefit-risk in relation to quality, safety, and efficacy.

The National Institute for Health and Care Excellence (NICE) is responsible for providing evidence‑based recommendations on whether new, licensed medicines represent a clinically and cost‑effective use of National Health Service resources. Daraxonrasib is not currently included in NICE’s work programme. If the manufacturer submits a licensing application to the MHRA for daraxonrasib it will be considered by NICE for evaluation. If selected for NICE appraisal, NICE would aim to issue guidance on its use as close as possible to licensing.